BMS's Zenbexus was approved on a proxy marker. Survival data is still years away.

On 13 August, the FDA granted accelerated approval to iberdomide (Zenbexus), Bristol Myers Squibb's first drug in a new class called a CELMoD, in combination with daratumumab and dexamethasone for adults with multiple myeloma who have already been through a proteasome inhibitor and an immunomodulatory drug.

That is the fourth line of description most coverage led with. The one worth sitting on is what the approval was actually based on: not how long patients lived, but how many of them had no cancer the trial's tests could find.

What the FDA actually approved on

The efficacy population was 420 patients out of the 939 randomized in the EXCALIBER-RRMM trial (NCT04975997). The endpoint was minimal residual disease (MRD)-negative complete response: a bone marrow test sensitive enough to detect one cancer cell in 100,000, run on patients who'd already reached a complete response by standard measures.

That is a surrogate endpoint: a stand-in the FDA accepts as reasonably likely to predict a real clinical benefit, without waiting to observe the benefit itself. It's the same regulatory device covered in this outlet's earlier piece on Replimune's RP1: approve now on a measurable proxy, confirm later on an outcome that actually matters to a patient.

Is 41% versus 21% a big deal?

Yes, by the trial's own numbers. 41% of patients on the iberdomide combination reached MRD-negative CR, against 21% on the comparator regimen (95% CI 34–48 versus 15–27, p<0.0001). Translated: doubling the share of patients whose bone marrow tested clean at the most sensitive threshold available, and the gap is unlikely to be chance.

What it does not tell you is how long that clean marrow lasts, or whether it translates into longer progression-free survival. MRD status correlates with outcomes across myeloma studies generally, and that is the premise the accelerated pathway rests on. But correlation in prior trials is not this trial's own confirmed result yet.

What the FDA is still waiting on

EXCALIBER-RRMM isn't finished. Its dual primary endpoint is progression-free survival, with overall survival tracked as a secondary endpoint under an independent data monitoring committee. The same trial that produced the MRD topline is the one that has to confirm the approval was justified. At the most recent interim look, the monitoring committee recommended the trial continue without modification, which is a mildly reassuring signal and not a result.

No public date has been given for when PFS matures. Until it does, Zenbexus stays approved on the strength of a marker the agency is betting will hold up, not on a demonstrated survival or progression benefit. That is the deal every accelerated approval makes, and it is worth being precise about which side of it you're on when the marketing describes this as simply "approved."

Why BMS needs this to work

This isn't a speculative pipeline addition. It's revenue replacement. Revlimid, BMS's longtime myeloma anchor, brought in nearly $3 billion in 2025 but fell by $2.8 billion from the year before as generics arrived, and Pomalyst is following the same downward path. Zenbexus is priced at roughly $28,000 a month, and analyst estimates published alongside the approval put peak sales above $1 billion by 2031. That is a forecast, not a disclosed figure, and one that assumes the drug displaces existing Revlimid-based regimens rather than simply adding to the mix.

The approval also carries a boxed warning for embryo-fetal toxicity and venous/arterial blood clots, and the drug is restricted to a REMS program — the same class of access controls that has slowed prescriber uptake for older drugs in this family. A REMS program doesn't stop a launch. It does add friction between an approval and the revenue an analyst model assumes will follow it on schedule.

What to watch

• The PFS readout, whenever BMS discloses it. That is the number that either confirms this approval or forces a label change — full approval is not automatic.
• Uptake speed under the REMS, since a restricted-distribution drug can miss its own sales model on timing alone, independent of whether the science holds.
• Mezigdomide, BMS's second CELMoD candidate, which the company has said succeeded in a separate late-stage myeloma trial — a second shot at the same franchise-replacement problem, running on a similar clock.

The portable lesson isn't specific to Zenbexus. When a headline says "FDA approves," the honest next question is what the approval was measured against. A drug cleared on a proxy marker and a drug cleared on survival data carry the same word, approved, and very different amounts of confirmed evidence behind it.

This is analysis, not investment advice. It describes what has been disclosed and what has not, and does not recommend any position in any security.